MediciNova is set to terminate its Phase II clinical trial of MN-001 (tipelukast) for the treatment of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia, based on the significant positive results from an interim analysis.

Results show MN-001 (tipelukast) to significantly reduce mean serum triglycerides, a primary endpoint of the trial, from 260.1mg/dL before treatment to 185.2mg/dL after eight weeks of treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

No clinically significant safety or tolerability issues were reported during the trial.

“We believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD.”

After achieving the most important endpoint of the trial, MediciNova plans to discontinue enrolment and cancel the study to speed up further development of MN-001.

MediciNova president and CEO Yuichi Iwaki said: “Based on the results of this study, along with the triglyceride data we have from prior clinical studies of MN-001 in other indications, we believe that MN-001 has potential to benefit a wide range of patients with hypertriglyceridemia, not limited to those with NASH and NAFLD.”

MN-001 (tipelukast) is a new, orally bioavailable small molecule compound.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has the potential to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE), and inhibition of 5-lipoxygenase (5-LO).

The open-label Phase II trial enrolled male and female patients aged between 21 and 65 years.

Participants had histologically confirmed diagnosis of NASH or imaging study confirmed NAFLD and an elevated serum triglyceride (>150 mg/dL).